TIL vs. PHAT, UPB, XNCR, MNMD, ABUS, EOLS, RLAY, KROS, DNA, and TYRA
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Phathom Pharmaceuticals (PHAT), Upstream Bio (UPB), Xencor (XNCR), Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Evolus (EOLS), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Ginkgo Bioworks (DNA), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.
Instil Bio vs. Its Competitors
Phathom Pharmaceuticals (NASDAQ:PHAT) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.
Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.
Instil Bio has lower revenue, but higher earnings than Phathom Pharmaceuticals. Instil Bio is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phathom Pharmaceuticals presently has a consensus price target of $17.50, suggesting a potential upside of 83.15%. Instil Bio has a consensus price target of $119.00, suggesting a potential upside of 276.64%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Phathom Pharmaceuticals.
Instil Bio has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Instil Bio's return on equity.
In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Phathom Pharmaceuticals and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Phathom Pharmaceuticals' score of 1.12 indicating that Instil Bio is being referred to more favorably in the news media.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 23.0% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 47.2% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Phathom Pharmaceuticals and Instil Bio tied by winning 7 of the 14 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TIL) was last updated on 7/25/2025 by MarketBeat.com Staff
Free TIL Stock Alerts